Cargando…

Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis

OBJECTIVES: To compare the risk of cardiovascular events from the initiation of therapy between metformin and dipeptidyl peptidase-4 inhibitors (DPP-4i) as first-line therapy. DESIGN: Retrospective cohort study using two claims databases. SETTING: The MDV database (provided by Medical Data Vision) c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishimura, Rimei, Takeshima, Tomomi, Iwasaki, Kosuke, Aoi, Sumiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919442/ https://www.ncbi.nlm.nih.gov/pubmed/35277396 http://dx.doi.org/10.1136/bmjopen-2020-045966

Ejemplares similares

Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study
por: Odawara, Masato, et al.
Publicado: (2021)

Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis
por: Nishimura, Rimei, et al.
Publicado: (2021)

A Claims Database Analysis of Dose-Dependency of Metformin and Incidence of Lactic Acidosis in Japanese Patients with Type 2 Diabetes
por: Nagai, Yoshio, et al.
Publicado: (2021)

Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
por: Nagai, Yoshio, et al.
Publicado: (2021)

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
por: Nishimura, Rimei, et al.
Publicado: (2019)

Validity of Claims Diagnosis Codes for Cardiovascular Diseases in Diabetes Patients in Japanese Administrative Database
por: Ono, Yasuhisa, et al.
Publicado: (2020)

Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
por: Batel-Marques, Francisco, et al.
Publicado: (2019)

A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands
por: de Groot, Saskia, et al.
Publicado: (2018)

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
por: Esposito, Katherine, et al.
Publicado: (2014)

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023)

Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)
por: Koshizaka, Masaya, et al.
Publicado: (2017)

Impact of deintensifying hypoglycaemic drugs in older adults with type 2 diabetes: protocol for an emulation of a target trial
por: Christiaens, Antoine, et al.
Publicado: (2023)

Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case–control study
por: Giorda, Carlo B, et al.
Publicado: (2015)

Use of multiple antidiabetic medications in patients with diabetes and its association with hypoglycaemic events: a case-crossover study in Jordan
por: Naser, Abdallah Y, et al.
Publicado: (2018)

Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
por: Cao, Fen, et al.
Publicado: (2021)

The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism
por: Yang, Qiu, et al.
Publicado: (2022)

Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis
por: Tricco, Andrea C, et al.
Publicado: (2014)

New Hypoglycaemic Therapies
por: Gale, Edwin A M
Publicado: (2000)

Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism
por: Trzaskalski, Natasha A, et al.
Publicado: (2020)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study
por: Kameda, Reina, et al.
Publicado: (2020)

Role and prevalence of impaired awareness of hypoglycaemia in ambulance service attendances to people who have had a severe hypoglycaemic emergency: a mixed-methods study
por: Duncan, Edward A S, et al.
Publicado: (2018)

Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022)

Treatment Status and Healthcare Cost Trends for Patients with Multiple Sclerosis in Japan: A Claims Database Analysis
por: Kawachi, Izumi, et al.
Publicado: (2022)

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial
por: Lundby-Christensen, Louise, et al.
Publicado: (2016)

A Principal Component Analysis Approach to Estimate the Disability Status for Patients with Multiple Sclerosis Using Japanese Claims Data
por: Kawachi, Izumi, et al.
Publicado: (2022)

Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes
por: Liu, Xu, et al.
Publicado: (2021)

Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study
por: Du, Guoli, et al.
Publicado: (2020)

Prevalence of idiopathic pulmonary fibrosis in Japan based on a claims database analysis
por: Kondoh, Yasuhiro, et al.
Publicado: (2022)

Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus
por: Shi, Qian, et al.
Publicado: (2019)

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2022)

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2023)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

RS3PE in Association With Dipeptidyl Peptidase-4 Inhibitor: Report of Two Cases
por: Yamauchi, Keishi, et al.
Publicado: (2012)

In Silico Approaches Applied to the Study of Peptide Analogs of Ile-Pro-Ile in Relation to Their Dipeptidyl Peptidase IV Inhibitory Properties
por: Nongonierma, Alice B., et al.
Publicado: (2018)

Metformin ameliorates insulitis in STZ-induced diabetic mice
por: Han, Xue, et al.
Publicado: (2017)

Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis
por: Sharma, Manuj, et al.
Publicado: (2017)

Prevalence of Vitamin B12 Deficiency in Patients with Type II Diabetes Mellitus on Metformin: A Study from Khyber Pakhtunkhwa
por: Khan, Adnan, et al.
Publicado: (2017)

Treatment pathways in people with type 2 diabetes mellitus: a nationwide cohort study of new users of metformin monotherapy in New Zealand
por: Guo, Joyce, et al.
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibitors Cause Bullous Pemphigoid in Diabetic Patients: Report of Two Cases
por: Pasmatzi, Efi, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_t5br5vqrtq6r8j5s7av5ilt21j